Chronic kidney disease (CKD) is highly prevalent in persons with type 2 diabetes (T2D). Patients with T2D and CKD are at high cardiovascular risk. To diagnose CKD and assess risk requires measuring and monitoring kidney function by both estimated globmerular filtration rate (eGFR) and urine albumin (proteinuria) in order to deliver goal-directed therapies. SGLT2 inhibitors, GLP-1 receptor agonists, and a non-steroidal mineralocorticoid receptor antagonist (MRA), along with a conventional ACE inhibitor or ARB therapy, are recommended therapies for persons with diabetes and CKD for both kidney and heart organ protection. 

  In this interview, Erin D. Michos MD, MHS, FACC, FAHA, FASE, FASPC, and William E. Boden MD, FACC, FAHA, discuss cardiovascular considerations of chronic kidney disease. 

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL